Gene Query: TP53

Dataset Description Geneva Score
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 249.06
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 249.06
RNA-sequencing of human leukemia cells and mouse hematopoietic progenitors 88.29
Genetic and pharmacological restoration of TET2 function blocks stem cell self-renewal and progression of leukemia 88.29
XPO1 inhibition antagonizes MCL via nuclear retention of IkB: Selinexor demonstrates antitumor activities in both ibr-sensitive and ibr-resistant tumor cells 86.02
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells 82.02
Effect of from Human Umbilical Vein Endothelial Cells 77.3
Transcriptome of human keratinocytes with or without HPV16 oncogene expression 68.79
RNA seq data of Hep3B-control, Hep3B-sertraline, Hep3B-XL413, Hep3B-XL413-sertraline, Huh7-control, Huh7-sertraline, Huh7-XL413, Huh7-XL413-sertraline cells 64.76
RNA-seq analysis of AML cells in response to ASLAN003 62.86
Gene expression profile of LMSU gastric cancer cell p53 KO and KD 53.25
Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection 52.19
Suppression of ribosomal pausing by eIF5A is necessary to maintain the fidelity of start codon selection (RNA-sequencing) 52.19
Understanding the Mechanistic Contribution of Herbal Extracts in Compound Kushen Injection with Transcriptome Analysis 49.14
RNA-seq in SUNE-1 cells after downregulation of DANCR expression 47.02
Differentiation enhances Zika virus infection in neuronal brain cells 46.33
mRNA-sequencing of U87 glioblastoma and DAOY medulloblastoma spheroidal aggregates undergoing electrotaxis 45.96
A TGFbeta-PRMT5-MEP50 Axis Regulates Cancer Cell Invasion through Histone H3 and H4 Arginine Methylation Coupled Transcriptional Activation and Repression 44.66
Quantitative analysis of bi-modal binding of BET proteins at promoters predicts I-BET sensitivity 41.1
RNA-seq analysis of control and CDK12-depleted ovarian cancer cells 39.18
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia [RNA-Seq] 39.16
Endogenous retroviruses are a source of oncogenic enhancers in acute myeloid leukemia 39.16
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma 38.37
Identification of altered developmental pathways in human juvenile HD iPSC with 71Q and 109Q using transcriptome profiling 36.8
Co-regulation of splicing by Rbfox1 and hnRNP M [hnRNPM k-d+Rbfox1 RNA-Seq] 36.76
Co-regulation of splicing by Rbfox1 and hnRNP M 36.76
The anti-leukemic effect of R-2HG depends on its acting as an m6A mRNA modifier-RNA Seq-PBS / R-2HG treatment 36.28
Identifying the molecular mode of action of itraconazole in colorectal cancer 35.58
Genome-wide functional assessment of enhancer activities in the human genome 35.0
RNA-Seq to assess the transcriptional effects of G quadruplex stabilization by the G4 ligand PhenDC3 in HT-1080 cells 34.43
Dtx3L and Androgen Signaling in Prostate Cancer 34.4
Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas 34.32
RNA sequencing of BT142 and TS603 cell lines 34.32
Glutaminolysis is a metabolic dependency in FLT3 ITD Acute Myeloid Leukemia unmasked by FLT3 Tyrosine Kinase Inhibition 34.0
HNRNPM-regulated splicing dependencies in prostate cancer 32.89
HNRNPM-regulated splicing dependencies in prostate cancer [RNA-Seq] 32.89
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation 31.96
Bladder cancer associated mutations in RXRA activate peroxisome proliferator-activated receptors 31.96
Cooperation between TLX1 and the NUP214-ABL1/STAT5 signaling in T-cell acute lymphoblastic leukemia 30.74
Investigsting the role of NF-ĸB p50 S80 phosphorylation in regulating TNFα-induced transcription in HEK293T cells 29.2
The role of FAM46C in myeloma cells 28.96
The role of FAM46C in myeloma cells [sequencing] 28.96
Splicing and epigenetic factors jointly regulate epidermal differentiation 28.6
Multiplex Single Cell Profiling of Chromatin Accessibility by Combinatorial Cellular Indexing 27.98
Multiplex Single Cell Profiling of Chromatin Accessibility by Combinatorial Cellular Indexing [RNA-seq] 27.98
RNA helicase A is necessary for KIF1Bβ tumor suppression in neuroblastoma 26.62
RNA-seq analysis of control and ZC3H18-depleted ovarian cancer cells 26.38
Biological effect of chronic mistranslation in mammalian cells 26.36
Potent and targeted activation of HIV-1 using the CRISPR/Cas9 activator Complex 25.85
The lung-enriched p53 mutants V157F and R158L/P regulate a novel transcriptome in lung cancer 25.47
Quantitative Analysis of negative control and overexpression-TRIB1 in PC3 and DU145 Transcriptomes 25.22
Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia (RNA-seq of KLF6 KO) 25.17
miR-450a acts as a tumor suppressor in ovarian cancer by readjusting energy metabolism 24.92
Heterozygous p53-R280T mutation promotes proliferation of NPC cells through activating PI3K/Akt signaling pathway 24.45
Effect of REST on cancer invasiveness in MCF-7 and MDA-MB-231 cells using RNA-sequencing (RNA-seq) analysis . 24.33
The effects of U1 snRNA mutation in chronic lymphocytic leukemia cell lines 23.89
Epigenetic silencing of the tumor suppressor RASSF4 favors multiple myeloma progression 23.87
MULTI-seq: Universal sample multiplexing for single-cell RNA sequencing using lipid-tagged indices 23.73
RBM25 is a global splicing factor promoting inclusion of alternatively spliced exons 23.67
A NIK-SIX signaling axis controls inflammation by targeted silencing of noncanonical NF-κB 23.59
‘Naïve’ ESRRB+ iPSCs with the capacity for rapid neural differentiation 23.48
hTERT promotes cell adhesion and migration independent of telomerase activity 23.29
CpG dinucleotides introduced into gag can inhibit HIV-1 gene expression by modulating pre-mRNA splicing 23.24
Genome-wide chromatin analysis of Ewing sarcoma (RNA-seq) 23.08
Genome-wide chromatin analysis of Ewing sarcoma 23.08
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis 22.8
KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis [RNA-Seq] 22.8
Transcriptional changes after overexpression of proliferation drivers in human mammary epithelial cells. 22.71
Gene expression in PANC-1 and AsPC-1 human pancreatic carcinoma cells under hypoxia, nutrient starvation and low pH culture condition. 22.71
PANC-1 and AsPC-1 human pancreatic carcinoma cells under hypoxia, nutrient starvation and low pH culture condition 22.71
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer 22.62
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq) 22.62
microRNA suppresses prostate cancer stem cells and metastasis by inhibiting a cohort of pro-metastasis targets including CD44, Rho GTPases and EZH2 22.58
Supraphysiological Androgens Repress Prostate Cancer Growth and Induce DNA Damage Augmented by PARP Inhibition 22.16
RNA-Seq in two Ewing sarcoma cell lines: A673 and SKNMC 22.12
Single-cell transcription profiling in KS1 patient iPSCs and NPCs 21.91
Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization 21.91
Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_sgrna] 21.74
RNA-seq analyses of human prostate cancer cells 21.54
A histone H3.3 Lysine 36 Trimethylation Reader Connects Chromatin to Regulated Pre-mRNA Processing 21.19
N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis[Ribosome Profiling] 20.7
EP400 is required for Max and MCPyV mediated gene activation 20.3
Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 20.09
RNA-seq Analysis of Castration-Resistant Prostate Cancer With Knock-down of E2F1 19.93
RNA-sequencing in irradiated and normal A549 cells. 19.9
Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma 19.86
NET-CAGE Characterizes the Dynamics and Topology of Human Transcribed Cis-regulatory Elements 19.79
Effects of Belinostat and Dexamethasone treatment of A549 gene expression 19.75
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived AREG 19.72
RNA-seq in transgenic cells 19.67
Effects of Inhibition of CDK8/19 Mediator Kinase by Senexin B in HEK293 cells treated with or without TNF-alpha 19.57
Self-organization of polarized cerebellar plate neuroepithelium in three-dimensional culture of human pluripotent stem cells 19.48
Transcriptomic profiling of O-GlcNAcylated mRNA-protein complexes by using OG-CLAP in HeLa cells. 19.39
Global transcriptional profiling changes upon knockdown of LKB1 in human glioblastoma cell lines 19.27
Phosphatase inhibitor PPP1R11 modulates resistance of human T cells towards Treg-mediated suppression of TCR signaling 19.24
Expression profile of HNF1A knockdown and overexpression in 22RV1 and LNCaP cells respectively 19.13
The effect of Abl kinases on non-small cell carcinoma global transcriptome 18.98
The RNA helicase DDX6 regulates self-renewal and differentiation of human and mouse stem cells [RNA-Seq] 18.66
Biosynthesis of histone messenger RNA employs a specific 3' end endonuclease 18.62
Transcriptomic profiling of HeLa cells infected with Salmonella Typhimurium 18.44
RNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of C1s. 18.41
A prostate cancer chromatin interaction map 18.37
The ALK downregulated target gene HBP1 and repressor of MYCN activity as synergistic target for combined PI3K/HDAC inhibition 18.33
The ALK downregulated target gene HBP1 and repressor of MYCN activity as synergistic target for combined PI3K/HDAC inhibition [RNA-Seq] 18.33
MYCi975 regulates MYC target genes 18.27
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells 18.24
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells [RNA-seq] 18.24
H9-hESC derived human neural stem cells with combinations of mutant IDH1-R132H overexpression, P53 shRNA knockdown and/or ATRX shRNA knockdown 18.14
RNA-seq of H9-hESC derived human neural stem cells with combinations of mutant IDH1-R132H overexpression, P53 shRNA knockdown and/or ATRX shRNA knockdown 18.14
Reciprocal Reprogramming of Cancer Cells and Associated Mesenchymal Stem Cells in Gastric Cancer. 18.1
Inhibition of SF3B1 by molecules targeting the spliceosome in Rh18 cells 18.0
Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion 17.87
Genome-wide CRISPR-Cas9 screen identifies SLC1A3 as a key contributor to L-asparaginase Resistance in Solid tumors 17.41
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 17.28
TCF7L1 knockdown in pancreatic cancer 17.08
RNA-sequencing experiment: Treatment of MCF-7 breast cancer cells with the novel small molecule ZNA 17.0
Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines 16.99
Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines [RNA-Seq] 16.99
Selective suppression of endothelial cytokine production by progesterone receptor 16.82
Selective suppression of endothelial cytokine production by progesterone receptor [RNA-seq] 16.82
In vitro differentiation of human low threshold mechanoreceptive (LTMR) neurons from embryonic stem cells 16.82
Safeguarding nucleolar homeostasis by CBX4 alleviates senescence and osteoarthritis 16.78
Parkinson’s Disease Genetic Risk in a Midbrain Neuronal Cell Line 16.38
A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo 16.37
GCTM-5 positive and negative cells in pancreatic adenocarcinoma cell lines 16.34
Genome-wide expression change by SHARPIN knockdown in MCF-7 cells 16.33
Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in acute myeloid leukemia. 16.11
Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+ T regulatory cells activation 16.04
RNAseq of T-ALL upon long non coding rna purturbation 15.99
Overexpression of UGT2B17 in MEC1 and JVM2 leukemia cell lines 15.78
Gene expression data from IMR90 control, IMR90 shRRM2 and shRRM2/shp16 15.76
Identification of Nrf2 regulated genes by RNA sequencing 15.76
Nrf2 regulated genes in A549 cells 15.76
RNA-seq analysis of human cardiosphere cells with different tubule supportive potential 15.71
RNA sequencing of GlyH-101-treated MCF-7 cell line 15.67
A549 cell transcriptome responses to infection with H7N9 influenza virus 15.49
SETDB1 compacts the inactive X chromosome in part through silencing an enhancer in the IL1RAPL1 gene 15.46
Functional Importance of eRNAs for Estrogen-dependent Gene Transcriptional Activation 15.39
RNA-Seq and ChIP-Seq reveals SQSTM1/p62 as a key mediator of JunB suppression of NF-kB-dependent inflammation 14.99
JunB control of keratinocyte-mediated inflammation [RNA-seq] 14.99
Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma: RNA-sequencing of PEL cell lines during KSHV reactivation 14.92
RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1 14.89
Forkhead domain mutations in FOXA1 drive prostate cancer cell progression 14.89
Quantitative Analysis of p53 and/or TGFBR2 Knockdown Endothelial Transcriptomes after Irradiation 14.87
The mechanism of HHT in treating acute myeloid leukemia on RNA level. 14.79
G-quadruplex structures mark human regulatory chromatin 14.61
Drug combination of 17-AAG and Belinostat on MDA-MB-231 breast cancer cells 14.55
Transcriptome analysis of H9 hESC derived cerebral organoids 14.44
A CLK3-HMGA2 alternative splicing axis impacts human hematopoietic stem cell molecular identity throughout development [BM low-input mRNA-seq] 14.34
MCF10A H-Ras RNA-Seq 14.32
Next Generation Sequencing Facilitates Quantitative Analysis of human patient derived primary Glioblastoma (GBM) cancer cell Transcriptomes 14.26
Gene expression analysis of breast cancer cell-lines 14.12
Gene expression and genome-wide location analysis of breast cancer cell-lines 14.12
Human gut derived-organoids as model to study gluten response and effects of microbiota bioproducts in celiac disease 14.06
Appropriately Differentiated ARPE-19 Cells Regain a Native Phenotype and Similar Gene Expression Profile 14.03
Effect of selective glucocorticoid receptor modulation (SGRM) on gene expression in human prostate cancer cell lines 13.93
Small molecule targets TMED9, promotes lysosomal degradation to reverse proteinopathy 13.91
A role for p53 in the adaptation to glutamine starvation through the expression of Slc1a3 13.9
Modulation of SF3B1 causes global intron retention and downregulation of the B-cell receptor pathway in chronic lymphocytic leukemia 13.86
Transcriptome of TNF-a-treated and untreated HeLa cells before and after TFIIB knockdown 13.8
mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4 13.8
RNA-seq and m6A-seq of AML cells with FTO knockdown or inhibition 13.71
Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) 13.66
Plasma cell mitochondrial pyruvate import controls the duration of humoral immunity. 13.65
RNAseq of quiescent (Q) and stress induced premature senescent (SIPS) fibroblasts treated with plant extract (1201) from Solidago vigaurea subspecies alpestris 13.55
Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells. 13.47
Synergy from Gene Expression and Network Mining (SynGeNet) method predicts genotype-specific synergistic drug combinations in melanoma 13.45
Synectin Promotes Fibrogenesis by Regulating PDGFR Isoforms Through Distinct Mechanisms 13.39
Identification of Resistance Genes to BRAF Inhibitor in Melanoma by piggyBac Transposon Activation Mutagenesis Screen 13.25
Comparative whole-transcriptomic analysis between normal and AKAP-Lbc-depleted human embryonic stem cells 13.22
Temporal dynamic reorganization of 3D chromatin in hormone-induced breast cancer and endocrine resistance 13.15
Integrative classification of human coding and non-coding genes based on RNA metabolism profiles 13.14
SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival 13.13
Transcriptomic profiling of human coronary artery endothelial cells under laminar shear stress (LS), oscillatory shear stress (OS) and static culture (ST) 13.07
Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed 13.03
Capturing the biology of mild versus severe disease in a pluripotent stem cell-based model of Familial Dysautonomia 12.91
RNA-seq of tumor cells following angiopellosis extravasation 12.81
Insights into snoRNA biogenesis and processing from PAR-CLIP of snoRNA core proteins and small RNA sequencing 12.76
scRNASeq analysis of cycling cardiomyocytes 12.73
Transcriptional profile of human STAT1-/- fibroblasts expressing LY6E or empty control vector 12.57
Single Cell Analysis Reveals Unexpected Transcriptional Heterogeneity of Neural Progenitors in the Developing Human Cortex 12.43
Apatinib preferentially inhibits Gefitinib-resistant lung cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway 12.42
RNA-sequencing of human mammary epithelial cells (HMLEs) transduced in vitro with a shRNA against SOX4 or a scrambled shRNA in untreated and TGF-β-treated (16 hours) conditions 12.15
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma 12.13
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression [ELL2 KO] 12.09
H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [Nalm-6] 12.04
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation [RNA-Seq] 12.03
Dynamic and stable enhancer-promoter contacts regulate terminal differentiation 12.03
Peroxisome Proliferator-activated Receptor gamma- Deficiency in Endothelial Cells Impairs Angiogenic Capacity by Loss-of E2F1 Mediated Wnt Effector Genes 11.99
A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging 11.93
DUX4-induced dsRNA and MYC mRNA Stabilization Activate Apoptotic Pathways in Human Cell Models of Facioscapulohumeral Dystrophy 11.91
The X-linked DDX3X RNA helicase dictates translation re-programming and metastasis in melanoma 11.86
Comprehensive analysis of Long non-coding RNA expression in dorsal root ganglion reveals cell type specificity and dysregulation following nerve injury 11.83
Comprehensive analysis of Long non-coding RNA expression in dorsal root ganglion reveals cell type specificity and dysregulation following nerve injury [human iPS] 11.83
A compendium of promoter-centered long-range chromatin interactions in diverse human tissues and cell types 11.77
m6A-seq data analysis of control and PCIF1 knockdown transcriptome 11.64
Sodium butyrate ameliorates aSyn-induced transcription deregulation and DNA damage 11.63
Overexpression of PHF8 promotes an EMT-related gene signature in MCF10A cells 11.54
JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML 11.52
Transcriptional profiling of MDA-MB-231 and its ρ0 cells (lacking mtDNA) after 48h arginine depletion by arginine deiminase (ADI). 11.51
FMRP facilitates the nuclear export of N6-methyladenosine-containing mRNAs 11.5
In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin. 11.49
A novel target of EZH1/2 for treatment of mantle cell lymphoma 11.48
Endometrial transcriptome and PGR cistrome in cycling fertile women [RNA-seq] 11.44
Endometrial transcriptome and PGR cistrome in cycling fertile women 11.44
Transcriptome analysis upon C6orf203 silencing 11.4
Cell-to-cell variation in defective virus expression and effect on host response during influenza virus infection 11.37
ChIP-seq and RNA-seq from human lymphoma cell lines 11.34
RNA-seq data from human lymphoma cell lines 11.34
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived SPINK1 11.33
Histone Demethylase-Assisted Somatic Cell Nuclear Transfer Facilitates Derivation of Human Pluripotent Stem Cells 11.23
A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity 11.22
Molecular Mechanisms of Endothelial Hyperpermeability 11.15
Transriptional profiling upon heat shock and recovery in cells deficient for FBXW7 and their wild type counterpart. 11.11
FBXW7 modulates stress response by post-translational modification of HSF1 11.11
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA 11.11
AMPK signaling for naïve pluripotency [Hs] 11.09
AMPK signaling for naïve pluripotency 11.09
A SIRT1-centered Circuitry Regulates Breast Cancer Stemness and Metastasis 11.07
Altered mRNA splicing by mutant p53 activates oncogenic RAS in pancreatic cancer 11.05
RNA-seq analysis of FET cells treated with RSPO1 or TGFβ1 10.99
Expression profiling of MCF-7 cells with 10nM treatment of TCDD 10.93
Expression profiling of MCF-7 cells with treatment of TCDD 10.93
PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer 10.92
Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis [RNA-Seq] 10.87
Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis 10.87
Downregulation of LATS kinases alters p53 to promote cell migration 10.82
RNA sequencing analysis of human embryonic stem cells and axial progenitors 10.8
Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells (2) 10.8
Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells 10.8
Aberrant downstream mechanisms following loss of KMT2C and KMT2D in Pancreatic Ductal Adenocarcinoma 10.76
The translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders 10.73
Long non-coding RNA SMILR regulates genes involved in cytokinesis in human vascular smooth muscle cell 10.68
Transcriptional landscape changes during human embryonic stem cell derivation 10.67
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data 10.67
Brain organoids reproducibly generate the cellular diversity of the human cerebral cortex 10.66
Transcriptional responses of melanoma cells to BRAF inhibition 10.64
CRISPR adenine and cytosine base editors with reduced RNA off-target activities 10.63
CRISPR adenine and cytosine base editors with reduced RNA off-target activities [CBE] 10.63
Effect of ROQUIN2(Y691F) expression on mRNA levels upon BCR stimulation 10.59
LncRNA NMR knockdown and overexpression in esophageal squamous cell carcinoma cell lines 10.57
Nucleotide stress induction of HEXIM1 suppresses melanoma by modulating cancer cell-specific gene transcription [RNA-Seq2] 10.54
Long Non-coding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity 10.48
An integrative analysis of non-coding regulatory DNA variations associated with autism 10.45
Identification of global regulators of T-helper cell lineage specification (RNA-Seq) 10.44
Identification of global regulators of T-helper cell lineage specification 10.44
TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression 10.43
Gene expression analysis of CD4+ and CD4- ILC1 subsets by RNAseq 10.4
Human Nonsense-Mediated RNA Decay Initiates Widely by Endonucleolysis and Targets snoRNA Host Genes 10.4
Precise Gene Editing Preserves Hematopoietic Stem Cell Function Following Transient p53-Mediate DNA Damage Response [bulk RNA-seq] 10.37
Next Generation Sequencing Facilitates Quantitative Analysis of transcriptomes of human cord blood CD34+ cells treated with HDAC5 inhibitor 10.37
ARID2 promotes clear cell renal cell carcinoma in the absence of functional PBRM1 10.31
ARID2 promotes clear cell renal cell carcinoma in the absence of functional PBRM1 [RNA-seq] 10.31
Valproic acid attenuates hyperglycemia induced complement and coagulation cascade gene expression 10.31
Human pluripotent stem cell-derived brain tumor model uncovered embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor (RNA-Seq) 10.3
Gene expression profiling of LNCaP cells following shRNA-mediated knockdown of TMEFF2 and growth in presence and absence of dihydrotestosterone 10.29
Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells (RNA-seq) 10.15
Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells 10.15
Uridylation-mediated RNA quality control pathway in mammalian cytoplasm [RNA-Seq] 10.13
TUT-DIS3L2 is a mammalian surveillance pathway for aberrant structured non-coding RNAs. 10.13
Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs 10.07
Transcriptomic analysis of cultured corneal endothelial cells as a validation for their use in cell-replacement therapy 10.02
Human germ cell formation in xenotransplants of induced pluripotent stem cells carrying X chromosome aneuploidies 10.02
LncPRESS1 is a p53-regulated lncRNA that safeguards pluripotency by disrupting SIRT6 mediated de-acetylation of histone H3K56 9.98
Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells 9.94
Gene target specificity of the Super Elongation Complex (SEC) family: How HIV-1 Tat employs selected SEC members to activate viral transcription 9.93
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-dependent Tumors 9.85
IL-33 activates tumor stroma to promote intestinal polyposis 9.83
AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition 9.8
Androgen Receptor-regulated genes in prostate cancer cells 9.8
RNA-seq profiling identifies Androgen Receptor-regulated genes in prostate cancer cells 9.8
Deletion of DXZ4 on the human inactive X chromosome eliminates superdomains and impairs gene silencing 9.79
Transcriptome profiling of the interconnection of pathways involved in malignant transformation and response to hypoxia 9.74
RNA-Seq analysis of neurons derived from induced pluripotent stem cells reprogrammed from dental pulp 9.73
Decrease in EZH2 histone methyltransferase mediates the effects of fluid shear stress (FSS) in endothelial cells 9.72
MUC1-C Drives Lineage Plasticity in Progression to Neuroendocrine Prostate Cancer 9.71
Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2 9.7
Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2 [RNA-seq] 9.7
Recruiting Endogenous ADARs with Antisense Oligonucleotides to Reprogram the Transcriptome 9.64
RNA deep sequencing to compare genome-wide differences between PRMT5/knockdown and control AML cells 9.64
Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR- PCa cells 9.59
RNA expression profiling of human mPB or CB-derived CD34+ cells treated with UM171 at different doses 9.59
Cell-specific expression and function patterns of microRNA-150-5p in liver fibrogenesis 9.55
Mllt3 Governs Self-Renewal And Engraftment Of Human Hematopoietic Stem Cells 9.5
RNA-seq of MLLT3-overexpressing cultued HSPC, compared to non-overexpressing and uncutured FL-HSPC [RNAseq_MLLT3_OE] 9.5
Accurate annotation of human protein-coding small open reading frames 9.48
Cerebellar differentiation in Ataxia-Telangiectasia 9.44
Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of BET inhibitor JQ1 9.43
Modeling and characterization of the dynamic gene regulatory networks underlying cancer drug resistance based on time-course RNA-seq data 9.35
SIGNAL INTEGRATION AND TRANSCRIPTIONAL REGULATION OF THE INFLAMMATORY RESPONSE MEDIATED BY THE GM-/M-CSF SIGNALING AXIS IN HUMAN MONOCYTES [RNA-seq] 9.29
SIGNAL INTEGRATION AND TRANSCRIPTIONAL REGULATION OF THE INFLAMMATORY RESPONSE MEDIATED BY THE GM-/M-CSF SIGNALING AXIS IN HUMAN MONOCYTES 9.29
LED, a long non-coding RNA activator of enhancer RNAs, is hypermethylated in human cancers 9.24
Genome-wide Gene Expression Profiling in DLBCL Cell Lines Treated with CUDC-907 9.23
Transcriptomic analysis of healthy donor and Sickle Cell Disease (SCD) hematopoietic stem/progenitor cells 9.23
RNA sequencing of primary human platelets and in vitro cell lines 9.21
AhR activity directs BRAF inhibitors resistance in metastastic melanoma 9.2
IRF1 regulates IFN dependent and independent gene expression 9.18
Comprehensive Transcriptome Analysis of Cerebral Cavernous Malformation Across Multiple Species and Genotypes 9.16
Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma 9.09
Cooperation of dominant oncogenes with regulatory variants shapes clinical outcomes in pediatric cancer 9.07
RNA-seq of three Ewing sarcoma cell lines (A673, SK-N-MC, RDES), transfected with either siControl or siMYBL2. 9.07
Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer 9.06
Gene expression profile of HGC27 and LMSU gastric cancer cell p53 KO and KD 9.04
RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells. 9.03
A novel CD4+ T cell population expanded in SLE blood provides B cell help through IL10 and succinate 8.99
RNA-seq of cultured human kidney peritubular microvascular endothelial cells following exposure to cyclosporine A 8.89
The Developmental Heterogeneity of Human Natural Killer Cells Defined by Single-cell Transcriptome 8.82
Engineered human pluripotent stem cell-derived intestinal tissues with a functional enteric nervous system 8.8
β-Caryophyllene Enhances the Transcriptional Upregulation of SREBP-dependent Lipid Biosynthesis in Breast Cancer Cells 8.78
Human iPSC-derived cells and microengineered Organ-Chip enhance neural development. 8.75
Human Sandhoff Disease Cerebral Organoids Exhibit Enlarged Size, Increased Cellular Proliferation, and Impaired Differentiation 8.75
Role of XRN2 ribonucleolytic activity in RNA metabolism 8.72
Metastasis in triple negative breast cancer is dependent on ΔNp63/CXCL2/CCL22-mediated recruitment of myeloid-derived suppressor cells 8.67
A novel RAF kinase inhibitor with DFG-out binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation 8.62
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma 8.62
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma [RNA-seq] 8.62
Activation of neuronal genes via LINE-1 elements upon global DNA demethylation in human neural progenitors 8.57
RNA-Guided Human Gene Activation by Cas9/CRISPR-Based Engineered Transcription Factors 8.52
mRNA sequencing of oropharyngeal cancer cell lines 8.52
Effects of Inhibition of CDK8/19 Mediator Kinase by Senexin B in HCT116 cells treated with or without TNF-alpha 8.37
Mitotically associated long non-coding RNA, MANCR regulates cell cycle in triple negative breast cancer cells  8.25
mRNA differential expression in LNCaP cells expressing the wild-type androgen receptor (AR-WT) or the ligand-independent AR-V7 splice variant 8.18
Differential expression in LNCaP cells expressing the wild-type androgen receptor (AR-WT) or the ligand-independent AR-V7 splice variant 8.18
Suppression of NAF-1 in Breast Cancer Cells Reduces their Tumorigenicity by Interfering with Cellular Iron Distribution and Metabolism and Ensuing ROS Formation and Apoptosis 8.1
Treatment of SW480 colon cancer cell induced xenografts with AZD and DBZ 8.1
Long non-coding RNA TYKRIL controls pericyte function and survival in the cardiovascular and central nervous system through regulation of p53 activity and PDGFRß expression 8.07
High throughput analysis of three human adipose cell lines PAZ6, SGBS and SW872 8.01
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression 7.96
Loss of CHD1 facilitates oncogenic hijacking of AR during cancer progression [RNA-seq] 7.96
Decoding breast cancer tissue-stroma interactions using species-specific sequencing 7.89
Identification of diverse target RNAs that are functionally regulated by human Pumilio proteins 7.87
Comparison of the transcriptome and chromatin state between human cord blood HSC and human iPSC derived hematopoietic progenitor using next-generation sequencing 7.78
Effect of MDK expressing Melanoma cells conditioned media in Human LEC 7.56
SREBP1 drives Keratin 80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ERα breast cancer 7.53
Effect of CRISPR-Cas9 mediated knock-out of integrin alpha2 on the transcriptome of DU145 prostate cancer cell grown as a spheroid culture 7.52
Zika virus infection reprograms global transcription of host cells to allow sustained infection 7.51
Transcriptomic Profiling of Developing Human Paraxial Mesoderm from 4.5-5 Weeks of Gestation Human Embryos 7.35
FOXA1 Chromatin Binding is Regulated by LSD1-Mediated Demethylation 7.28
RNA-Seq with DHT induction and/or GSK treatment at 24, 48 hrs and 2 weeks 7.28
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates Fasudil as an anti-leukemic drug. 7.18
Expression profiling and occupancy after knockdown or over-expression of HFN1A or HNF4G in prostate cancer cells 7.15
Total RNA deep sequencing (ribosomal depleted) of human umbilical vein endothelial cells exposed to hypoxia (0.2%) for 12h and 24h or kept under normoxic conditions. 7.08
Endothelial gene expression analysis 7.08
Antiviral innate immunity of hepatitis C virus-infected stem cell-derived hepatocytes 7.03
Evolution of an lncRNA leads to a primate specific modulation of alternative splicing 7.01
Transcriptomic analysis of senescent cells upon EXOC7 knockdown. 6.94
Identification of HOXB13 target genes responsive to BET inhibitors 6.94
The RNA-binding protein RBM47 suppresses metastatic breast cancer progression 6.91
Ultracentifugation and nanoscale deterministic lateral displacement (nanoDLD) of samples for exRNA analysis 6.88
Potential signaling pathways and gene signatures associated with brain metastases in NSCLC patients 6.85
C/EBPα overexpression overrides epigenetic reprogramming by RUNX1-ETO and RUNX1-EVI1 6.8
C/EBPα overexpression overrides epigenetic reprogramming by RUNX1-ETO and RUNX1-EVI1 [RNA-seq] 6.8
Transcriptome profiling of 5 human adenocarcinoma cell lines 6.61
Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer 6.55
Global host gene expression changes in KSHV+ PEL cells upon KSHV reactivation 6.44
Transcriptome-wide identification of transient RNA G-quadruplexes in human cells 6.43
Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers 6.38
Characterisation of the myeloid differentiation process of human hematopoietic stem cells 6.01
Indoxyl sulfate stimulates angiogenesis by regulating reactive oxygen species production via CYP1B1 5.99
Chemotherapeutic drugs inhibiting Topoisomerase 1 activity inhibit TNF-induced inflammatory gene expression 5.95
GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance 5.86
CDK12 inhibition in Hep3B, Huh7 and SNU449 cells 5.79
Genes significantly down or Up-regulated upon RNF219 knockdown. [RNA-Seq] 5.72
ChIPseq and RNAseq analysis of T47D cells with/without silencing TRPS1/CHD4 5.54
NGS based identification of GD2-positive tumor-specific phenotype for cancer diagnostics and therapy 5.49
Genome-wide Dose-dependent Inhibition of Histone Deacetylases Reveals Their Roles in Enhancer Remodeling and Suppression of Oncogenic Super-enhancers 5.44
Transcriptional profile of human STAT1-/- fibroblasts expressing IFI6 or empty control vector 5.4
The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner 5.33
RNA-Sequencing experiment for effects of PKF115-584 treatment on four T-ALL cell lines (RPMI8402, HPB-ALL, Jurkat, CCRF-CEM). 5.3
Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells 5.29
EZH2 inhibitor-mediated transcriptional profiling in prostate cancer cells [RNA-seq] 5.29
Distinct roles of cohesin-SA1 and cohesin-SA2 in 3D chromosome organization  5.29
Loss of ANCO1 repression of AIB1/YAP drives breast cancer progression 5.27
Searching for target genes of miR-508/509/506/514 in HCT116 cells 5.26
MPTAC determines APP fragmentation via sensing sulfur amino acid catabolism 5.23
Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics. [RNA-seq] 5.19
Molecular Signature of CAID Syndrome: Noncanonical Roles of SGO1 in Regulation of TGF-β Signaling and Epigenomics. 5.19
Regulation of stem cell property and drug resistance of cancer cells by targeting transcriptional machinery via inhibition of neddylation 5.17
Characterisation of the EZH2 regulated transcriptome in de novo transformed cells (RNA-Seq) 5.04
Transcriptomic analysis of acute mitochondrial pyruvate carrier inhibition using UK5099 in ABL prostate cancer cells 4.91
LHX9 rescues KRAS suppression through transcriptional regulation of YAP1 [RNA-Seq] 4.89
LHX9 rescues KRAS suppression through transcriptional regulation of YAP1 4.89
Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML) 4.82
mRNA expression in iPS cells generated by a synthetic self-replicative RNA 4.8
Regulation of poly(A) tail and translation during the somatic cell cycle 4.79
Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-FU-Mediated Cytotoxicity in Multiple Human Cancer Types 4.79
RNA-seq of IL-4 stimulated human keratinocytes 4.75
Systematic analysis of gene expression profiles controlled by hnRNP Q and hnRNP R, two closely related human heterogeneous nuclear ribonucleoproteins. 4.75
Inhibition of Enhancer of Zeste Homologue 2 attenuates TGF-β dependent hepatic stellate cell activation and liver fibrosis 4.74
The effect of REST and its alternatively spliced transcript, REST-003, on breast cancer invasiveness 4.73
High resolution ChIP sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma (RNA-Seq) 4.47
High resolution ChIP sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma 4.47
Profiling of circular RNAs in gastric cancer tissues and adjacent normal tissues 4.45
Ribosome profiling of TGFb-treated cells indicates reduced leucine availability 4.43
mRNAseq of Huntington's disease and control patient iPSC-derived brain microvascular endothelial cells 4.42
Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG 4.33
Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG [RNA-seq] 4.33
Modeling genome-wide transcriptional cis-regulation in n LNCaP-abl cell line after siRNA knock down of a series of gene factors [RNA-seq] 4.31
iPSC derived motor neuron cultures from C9ORF72 carriers 4.23
RNA-Seq of cKIT+ sorted cells from 53-137 day old fetal testes and ovaries and RNA-Seq of TRA-1-81+ H1 and UCLA1 hESCs. 4.21
cKIT+ sorted cells from 57-137 day old fetal testes and ovaries 4.21
Next-generation RNA sequencing to determine changes in gene expression during breast cancer progression 4.18
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-Seq KO] 4.05
Rapid Irreversible Transcriptional Reprogramming in Human Stem Cells Accompanied by Discordance between Replication Timing and Chromatin Compartment 4.02
Rapid Irreversible Transcriptional Reprogramming in Human Stem Cells Accompanied by Discordance between Replication Timing and Chromatin Compartment [RNA-Seq] 4.02
LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia (RNA-Seq) 4.02
LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia 4.02
Identifying markers predicting successful graft outcome for clinical translation of hESC-based cell therapy for Parkinson’s disease 3.99
AML subtype is a major determinant of the association between prognostic gene expression signatures and their clinical significance. 3.94
Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia 3.84
The MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in MLLr AML 3.84
The Molecular Dissection of the Oncogenic Role of ETS1 in the Mesenchymal Subtypes of Head and Neck Squamous Cell Carcinoma [RNA-seq Cell lines] 3.76
Expression profiling of pancreatic adenocarcinoma and ductal adenocarcinoma cell lines. 3.69
Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition 3.54
MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block 3.54
SMAD2/3 are redirected to novel sites in MCF10A MII after prolonged TGFβ stimulation 3.45
JUNB is a critical AP1 component for SMAD2/3 binding after TGFβ stimulation [RNA-seq] 3.45
The anti-leukemic effect of R-2HG depends on its acting as an m6A mRNA modifier-RNA Seq-Resistant, sensitive and healthy control 3.45
Transcriptome analyses of iPSC-derived neural stem/progenitor cells and cerebral organoids from monozygotic twins discordant for schizoaffective bipolar disorder 3.32
ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells 3.31
ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells (RNA-Seq) 3.31
Generation of low passage high grade serous ovarian cancer cell lines from primary tumors 3.28
Epigenomic conservation of transposable element silencing 3.03
Epigenomic conservation of transposable element silencing [RNA-seq] 3.03
Microsatellite expansion RNA visualization, elimination, and reversal of molecular pathology by RNA-targeting Cas9 2.95
RNA-Seq in PWS iPSC-derived neurons 2.94
RNA-seq analysis of YFV-17D specific and total naive CD8 T cells in humans 2.78
Genome Wide Chromatin Mapping of accessibility (ATAC-seq) and H3K27ac histone modifications in CD56bright and CD56dim natural killer cells 2.78
Insulin induced alterations in chromatin acetylation and transcriptome in triple negative breast cancer cells 2.67
Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells [RNA-seq] 2.67
Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells 2.67
CSL RNA-Seq on HKC and SCC cell lines 2.61
CSL 2.61
Apoptosis enhancing drugs overcome innate platinum resistance in CA125 negative tumor initiating populations of high grade serous ovarian cancer 2.6
Gene expression of thyroid cancer cell lines 2.56
Comparative Analysis of Cas9 Activators Across Multiple Species 2.55
Systematic Functional Perturbations Uncover a Prognostic Genetic Network Driving Human Breast Cancer 2.55
Systematic Functional Perturbations Uncover a Prognostic Genetic Network Driving Human Breast Cancer [RNA-Seq] 2.55
Altered Hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways [RNA-seq] 2.53
Altered Hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways 2.53
An intramolecular salt bridge linking TDP43’s RNA recognition motifs dictates RNA binding, protein stability and TDP43-dependent neurodegeneration 2.48
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression [ELL2 rescue] 2.46
Specific inhibition of DPY30 activity by peptides suppresses blood cancer cell growth 2.44
RNA-seq analysis of SLIRP knockdown with 1nM DHT in LNCaP cells 2.42
RNA-sequencing analysis of glucose and acetate regulated transcripts in glioblastoma cells 2.4
Trisomy of a ‘Down syndrome critical region’ globally amplifies transcription via HMGN1 overexpression [SLAM-Seq] 2.31
Direct interaction of MYCN and p53 regulate transcriptional responses in neuroblastoma 2.22
Direct interaction of MYCN and p53 regulate transcriptional responses in neuroblastoma [RNA-Seq] 2.22
Identification of long noncoding RNAs regulated by p53 2.1
Analysis of the senescent transcriptome upon expression of a ZFP36L1 phosphomutant 2.09
Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia (RNA-Seq of HSCe) 1.99
O-glcnAc reprograms cellular energetics 1.99
Human colon organoids reveal distinct physiologic and oncogenic Wnt responses 1.98
Genome-wide search for differentially expressed RNAs responsible for the effects induced by Ebola virus replication and transcription 1.94
Perlman syndrome nuclease DIS3L2 controls cytoplasmic non-coding RNAs and provides surveillance pathway for maturing snRNAs 1.91
RNA-sequencing of mRNAs from control and CAP-D3 deficient Salmonella infected HT-29 cells 1.89
Small-molecule-based Human Genome G4 Profiling Reveals Potential Gene Regulation Activity 1.88
Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells 1.87
SNHG5 siRNA knock down in HCT116 cells 1.86
Transcriptome-analysis of patient-derived normal and ulcerative colitis intestinal epithelial organoids 1.85
Identification of differentially expressed genes between senescence and senescence bypass cells 1.85
RNA-seq data 1.84
RNA sequencing from FOXM1 knockout HEK293T cells reconstituted with FOXM1 isoforms a, b and c. 1.81
Analysis of human ES cell differentiation establishes that the dominant isoforms of the lncRNAs RMST and FIRRE are circular 1.71
RNA-Seq analysis of cSCC cells after siRNA-induced gene knockdown of lncRNA PRECSIT 1.64
Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid 1.52
SMYD2 specificly regulate BIX-01294 induced TP53 target genes revealed by RNA-Seq 1.5
A MYC/GCN2/eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer 1.49
Molecular Signatures Associated with ZIKV Exposure in Human Cortical Neural Progenitors 1.45
Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers. 1.44
To identify transcripts that are differentially expressed in the MYCN amplified vs MYCN non-amplified cell lines using Next Generation Sequencing 1.39
Transcriptomic analysis to underly the heterogeneity between 4 cellular models derived from patients diagnosed with pediatric high-grade gliomas under controlled atmosphere (modulation of oxygen level). 1.38
RNA-Seq analysis of cSCC cells followed by siRNA-induced gene knockdown of AIM2. 1.35
Gene expression profiling associated with knockdown of RNF20 in human normal and malignant lung epithelial cell lines 1.35
The secretome of skin cancer cells activates the mTOR/MYC pathway in healthy keratinocytes and converts them into tumorigenic cells 1.31
Systems-level analyses reveal a convergent pathway for progression of diffuse astrocytoma and potential role for resveratrol in delaying high-grade transformation 1.11
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas 1.02
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas [RNA-Seq] 1.02
Widespread regulated alternative splicing of single codons accelerates proteome evolution 1.01
Transcriptional Profiling of Werner Syndrome (WS) iPSC-derived MSC and the isogenic gene-edited controls 0.88
RNA-Seq of CD34+ Bone Marrow Progenitors from Healthy Donors 0.86
A Reproducibility-Based Computational Framework Identifies An Inducible, Enhanced Antiviral Dendritic Cell State In HIV-1 Elite Controllers (TLR perturbation Bulk RNA-Seq) 0.85
Gene expression regulated by CSA and CSB in neuroblastoma cell line 0.85
Mutually Exclusive CBC-Containing Complexes Contribute to RNA Fate. 0.84
The p30 isoform of CEBPA uncovers a silent enhancer to drive the expression of the tumor promotive factor CD73 in CEBPA mutant AML 0.7
Tunable protein synthesis by transcript isoforms in human cells (Transcript Isoforms in Polysomes sequencing: TrIP-seq) 0.68
Solid phase chemistry to covalently and reversibly capture thiolated RNA 0.6
RNA-seq of healthy CD34+ HSPCs after co-culture with myelodyplastic syndrome patient-derived mesenchymal stromal cells 0.55
Identification of long noncoding RNAs in T-ALL cell lines 0.54
Finding missing proteins from epigenetically manipulated human cells 0.46
Transcriptional response of human endocervical epithelial A2EN cells to infection with wild-type or CpoS-deficient Chlamydia trachomatis L2/434/Bu 0.41
Differential LINE-1 retrotransposition in induced pluripotent stem cells between humans and great apes 0.39
RNA-Seq of Breast and Ovarian Cancer Cell Lines 0.32
Codon usage optimization in pluripotent embryonic stem cells [tRNA sequencing] 0.23
Transcriptomes change differerntly in differernt cancer cells upon EPZ-6438 treatment 0.13
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition 0.09
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition (RNA-seq) 0.09
Comparison of 7 small cell lung cancer PDX models, cultured ex vivo, for response to LSD1 inhibitor RG6016/ORY1001 0.05
Total RNA-Seq data from leukemic patients with complex structural variants 0.04
RelA mutants 'reconstituted' and cell cycle synchronized HCT116 Colorectal Cancer Cells 0.0


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation